



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

August 9, 2022

Paul Peter Tak, M.D., Ph.D.  
President and Chief Executive Officer  
Candel Therapeutics, Inc.  
117 Kendrick Street, Suite 450  
Needham, MA 02494

**Re: Candel Therapeutics, Inc.**  
**Registration Statement on Form S-3**  
**Filed August 5, 2022**  
**File No. 333-266605**

Dear Dr. Tak:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Margaret Schwartz at 202-551-7153 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Finn Murphy, Esq.